Frebourg T, Bercoff E, Manchon N, Senant J, Basuyau J P, Breton P, Janvresse A, Brunelle P, Bourreille J
Clinique Médicale A, C.H.U. de Rouen, Hôpital de Bois-Guillaume, France.
Cancer. 1988 Dec 1;62(11):2287-90. doi: 10.1002/1097-0142(19881201)62:11<2287::aid-cncr2820621103>3.0.co;2-h.
To establish if CA 19-9 could detect early pancreatic cancer, we measured its serum concentration in 866 patients admitted for benign diseases and observed for 2 years. All patients with an elevated CA 19-9 level (greater than 40 units (U)/ml) were submitted to a computed tomography (CT) scan of the pancreas. The CA 19-9 level was increased in 117 patients. One hundred fifteen of these 117 patients had false-positive elevations. The CA 19-9 concentration was elevated mostly in benign hepatobiliary diseases. In this group of patients, CA 19-9 was correlated to alkaline phosphatase values. Eleven patients showed an elevated CA 19-9 level for 10 months without any malignancy developing. One patient had a normal CA 19-9 concentration 8 months before clinical signs of pancreatic carcinoma developed. We conclude that CA 19-9 measurement is of no value for the early detection of this malignancy.
为确定CA 19-9能否检测早期胰腺癌，我们测定了866例因良性疾病入院并观察2年的患者的血清浓度。所有CA 19-9水平升高（大于40单位（U）/毫升）的患者均接受了胰腺计算机断层扫描（CT）。117例患者的CA 19-9水平升高。这117例患者中有115例出现假阳性升高。CA 19-9浓度大多在良性肝胆疾病中升高。在这组患者中，CA 19-9与碱性磷酸酶值相关。11例患者CA 19-9水平升高10个月，未发生任何恶性肿瘤。1例患者在胰腺癌临床症状出现前8个月CA 19-9浓度正常。我们得出结论，CA 19-9检测对这种恶性肿瘤的早期检测没有价值。
